Tecentriq-Abraxane Combo Reduces Risk of Worsening Disease, Death in Metastatic Triple Negative Breast Cancer, Phase 3 Trial Shows

Tecentriq-Abraxane Combo Reduces Risk of Worsening Disease, Death in Metastatic Triple Negative Breast Cancer, Phase 3 Trial Shows
Adding Tecentriq (atezolizumab) to the chemotherapy Abraxane (nab-paclitaxel) significantly delays the time to worsening disease or death in patients with metastatic triple negative breast cancer (TNBC), a Phase 3 trial shows. The combination is being studied in the IMpassion130 trial (NCT02425891) as a first-line treatment for metastatic TNBC patients and patients with locally advanced disease who cannot receive surgery. The therapy combination delayed disease progression in both the overall population and in patients with PD-L1 positive tumors, a biomarker that predicts response to Tecentriq. The combo met two of the trial's primary goals. Tecentriq, developed by Genentech, is a checkpoint inhibitor that removes the brakes from the immune system and restores tumor immune surveillance. The efficacy, safety, and pharmacokinetics of Tecentriq and Abraxane were compared to that of a placebo and Abraxane. Pharmacokinetics is the study of a therapy's absorption, distribution, metabolism, and excretion. A total of 902 patients were enrolled in the trial. Participants were randomly assigned Tecentriq or a placebo — given every two weeks — along with weekly chemotherapy at a schedule of three weeks on, one week off. Treatment was administered until patients experienced signs of disease progression or toxicity. In addition to extending the time a patient liv
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.